GLP-1 Gold Rush — Who’s Really Winning in the New Obesity Market?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
Host Tyler Cowan, VP Commercial at Syneos Health, joins Hruta Shah, Senior Engagement Manager for Syneos Health Consulting, to break down the high-stakes race in obesity treatment and the commercial boom around GLP-1 therapies.
You’ll hear:
- What emerging launch strategies look like in a crowded pipeline and how success is being redefined
- How GLP-1s are accelerating a shift in stakeholder dynamics, including telehealth, large employers and direct-to-patient platforms
- Why traditional DTC advertising is evolving and how informed patients are influencing brand messaging
The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.
If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub.
Like what you’re hearing? Be sure to rate and review us!
We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.